Analyst Price Targets — HIND
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| September 3, 2026 9:03 am | Keay Nakae | Chardan Capital | $3.50 | $2.18 | TheFly | Vyome initiated with a Buy at Chardan |
| October 2, 2025 11:39 am | — | Maxim Group | $15.00 | $5.50 | TheFly | Vyome Holdings upgraded to Buy from Hold at Maxim |
Latest News for HIND
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND--Vyome Holdings, Inc. (Nasdaq: HIND, “Vyome”), a clinical-stage biopharmaceutical company focused on immuno-inflammatory and rare disease conditions, today reports financial results for the second quarter ended June 30, 2026, and provides a corporate update. Krishna Gupta, Chairman, Vyome Holdings, said, “Vyome continues to execute with focus and discipline across its…
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $HIND #VT1953--Vyome Holdings, Inc. (NASDAQ: HIND) (“Vyome” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies for immuno-inflammatory and rare disease conditions, announces that the China National Intellectual Property Administration (CNIPA) has granted a patent (Chinese Patent No. ZL 2021 1 0758695.X) covering…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for HIND.
U.S. House Trading
No House trades found for HIND.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.